Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. This Business Profile tracks the Brand Authority Index and supporting AI visibility evidence. Last analyzed August 29, 2026.
Alnylam Pharmaceuticals is RNA and DNA Targeted Therapies.
Buyers turn to Alnylam Pharmaceuticals for Genetic diseases, Diseases caused by specific gene expression, Unmet medical needs in rare diseases, among 5 documented problem areas.
Buyers evaluating Alnylam Pharmaceuticals typically ask AI models about "RNAi therapeutic development", "Gene silencing treatments", "Innovative disease modifying medicines", and 2 similar queries.
Buyers commonly compare Alnylam Pharmaceuticals with Efficacy of RNAi therapeutics, Safety profile of Alnylam medicines, Clinical trial data for RNAi drugs, among 9 documented comparison brands.
Alnylam Pharmaceuticals's core products are RNA interference (RNAi) therapeutics for rare and prevalent diseases.
Alnylam Pharmaceuticals uses Not available in the text.
Alnylam Pharmaceuticals serves Patients suffering from rare and prevalent diseases addressable by gene silencing.
Alnylam Pharmaceuticals Pioneer and leader in RNA interference (RNAi) therapeutics, silencing disease-causing genes at their source to amplify life
Official website: https://alnylam.com/
Last analyzed: August 29, 2026
This Business Profile is published by Optimly in the Optimly AI Brand Index, a public research dataset showing how AI systems describe brands, categories, and competitors. Optimly AI Visibility analyzes sampled buyer-intent responses, cited sources, and public brand information. The Brand Authority Index summarizes answer presence, narrative accuracy, and owned citations where sufficient evidence is available.
If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile